IPD Analytics

IPD ANALYTICSA5 · direct accessManage supplier listing

A normalized, multi-domain market-access and drug-policy panel sold as the Access Hub subscription, assembled by an in-house clinical research team rather than scraped. Components: (1) Formulary coverage across national and regional insurers with per-drug status and restriction detail, normalized across plans and sliceable by drug, disease class and manufacturer portfolio. (2) Clinical criteria benchmarking collected from six major national plans, capturing every management step a plan applies to a specific therapy (step-therapy sequences, prior-auth criteria, quantity limits). (3) Limited distribution drug network tracking — which pharmacies are authorized to dispense each limited-distribution specialty drug and how those networks shift, an asset class the vendor states has historically been impossible for payers and providers to monitor because it is fragmented across sources. (4) Therapy cost analytics spanning current and historical drug costs at disease-class, manufacturer-portfolio and individual-drug level, including new brand approvals and competitor comparison. (5) A 750+ clinical guideline library used to anchor drug policies against published recommendations. (6) Biomarker test pricing, payer coverage, access and patient-assistance tracking for companion diagnostics. (7) Nonessential drug lists. (8) State Medicaid preferred-drug-list meeting tracking — meeting frequency, dates, agendas, outcomes and public comments, with drugs and indications indexed for follow-up.